Monoclonal antibody 7G7F9 against human protein kinase CPKC, nucleic acid, cell line and vector, and their uses and preparation methods
By developing highly specific and high-affinity monoclonal antibodies 4G7G5 and 7G7F9, the problems of unstable antibody preparation and difficulty in quantification in existing technologies have been solved, and the industrialization of efficient Alzheimer's disease diagnosis and treatment products has been realized.
Patent Information
- Application Number
- CN202611258018.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-19
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies lack monoclonal antibodies against human protein kinase CPKC with high specificity, stability, and high affinity, making it impossible to accurately identify and quantitatively capture natural PKCδ. Furthermore, the lack of complete preparation processes and quality control systems limits the translation of PKCδ targets from laboratory research to clinical diagnostic and therapeutic products.
Two highly specific monoclonal antibodies against human protein kinase CPKC, 4G7G5 and 7G7F9, were developed. Their complete set of variable region genes and cell lines were provided, a standardized preparation process was established, and surface plasmon resonance (SPR) technology was introduced for quantitative characterization. A long-acting preservation buffer was also provided to build a complete industrialization chain.
It has achieved the preparation of antibodies with high specificity and high affinity, with a purity of ≥90% and a titer of ≥1093.5K, filling the gap in quantitative binding kinetics, supporting the development of Alzheimer's disease diagnostic kits and targeted drugs, and opening up the industrialization chain from cell raw materials to diagnostic and therapeutic products.
Smart Images

Figure CN123106909A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the fields of genetic engineering and cell engineering, and in particular to the monoclonal antibody 7G7F9 against human protein kinase CPKC, as well as nucleic acids, cell lines and vectors, their uses and preparation methods. Background Technology
[0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline. Current diagnostic and treatment methods have limitations, including difficulty in early identification, treatment only relieving symptoms, and inability to reverse disease progression. There is an urgent need to discover novel biomarkers and targeted interventions. Existing research has confirmed that microglia-mediated neuroinflammation is a key driver of AD pathological progression, with protein kinase PKCδ playing a central regulatory role in this pathway. Related basic research findings have been published in the journal *Alzheimer's & Dementia* (Du Y et al., 2024, DOI:10.1002 / alz.14047). This paper serves as the preliminary foundational work for this invention, and its main research content and inherent limitations are as follows: Du, Y., Guo, T., Hao, Y., Li, C., Tang, L., Li, X., Zhang, X., Li,L., Yao, D., Xu, X., Si, H., Zhang, J., Zhao, N., Yu, T., Zhao, Y., Zhang,W., & Xu, H. (2024). PKCδ serves as a potential biomarker and therapeutic target for microglia-mediated neuroinflammation in Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. https: / / doi.org / 10.1002 / alz.14047 Core research content: 1. Validating PKCδ as a specific biomarker for Alzheimer's disease; the paper confirmed through clinical sample testing that the PKCδ protein level in the cerebrospinal fluid of Alzheimer's disease patients was significantly elevated, with a diagnostic receiver operating characteristic (AUC) of 0.9009, effectively differentiating Alzheimer's disease from Alzheimer's disease. Compared with healthy controls, PKCδ showed superior efficacy to traditional inflammatory factors such as IL-1β, IL-6, and TNFα, demonstrating its potential as a biomarker for early diagnosis and disease monitoring in Alzheimer's disease (AD). The study elucidated the molecular mechanism by which PKCδ mediates neuroinflammation in AD: It clarified that PKCδ is mainly expressed in central microglia, fully revealing the pathological pathway: Aβ deposition induces upregulation of PKCδ expression in microglia; overactivated PKCδ further activates the NF-κB inflammatory signaling pathway, releasing large amounts of pro-inflammatory factors and continuously exacerbating neuronal damage and chronic inflammation in the brain. Simultaneously, using an APP / PS1 AD model mouse, it was verified that downregulation or inhibition of PKCδ significantly reduced neuroinflammation in the brain and improved cognitive deficits in mice. This paper provides a basic approach to PKCδ function intervention. It uses two chemical inhibitors, roderin and siRNA, to inhibit PKCδ function and demonstrates that blocking PKCδ activity can alleviate AD-related pathological damage. It also discloses conventional molecular biology experimental methods such as qRT-PCR, Western Blot, RNA sequencing, immunofluorescence, commercial ELISA, animal model construction, and ROC curve analysis.The study confirmed the potential of PKCδ as a therapeutic target for Alzheimer's disease (AD). The overall research validated the findings from multiple dimensions, including clinical samples, cell experiments, and animal models. PKCδ is a key driver molecule of microglial neuroinflammation, serving as both a highly specific diagnostic biomarker for AD and a therapeutic target with significant development potential.
[0003] The inherent defects of the preliminary basic paper, namely the lack of existing technology, are that the paper only completed the basic scientific verification at the target mechanism level and did not realize the productization of the technological results. It has four major shortcomings, which are also the existing technological defects that this invention needs to solve. 1. Lack of targeting tool molecules that can specifically recognize naturally derived human PKCδ: The paper did not develop or disclose any anti-human PKCδ monoclonal antibodies or their corresponding amino acid and nucleic acid sequences, and contained no data related to specific targeted antibodies. Functional validation was performed using only the non-specific chemical inhibitors rodttlerin and siRNA. Rodttlerin, a pan-PKC family inhibitor, has poor target selectivity, severe off-target effects, and insufficient safety for in vivo application. siRNA is difficult to deliver and has poor stability, making it unsuitable for quantitative detection in clinical samples and long-term in vivo intervention, and unable to achieve accurate identification and quantitative capture of native PKCδ proteins.
[0004] 2. Antibody preparation and cell resources that lack standardization and can be stably mass-produced: The paper did not involve hybridoma cell construction or monoclonal antibody preparation technologies, did not disclose any hybridoma cell lines that can stably secrete anti-PKCδ specific antibodies, and lacked a complete set of standardized processes for immunization, cell fusion, subcloning, and antibody purification. Relying solely on commercially available general-purpose detection reagents, it is impossible to independently and stably obtain high-purity, high-activity specific antibodies, which makes it difficult to support the development of large-scale detection kits and in vivo targeted drug research and development.
[0005] 3. Lack of a quantitative affinity characterization system for PKCδ with target molecules: The paper did not introduce surface plasmon resonance (SPR) detection technology, completely lacked quantitative data on antigen-antibody binding kinetics, and lacked core affinity parameters such as binding rate constant Ka, dissociation rate constant Kd, and dissociation constant KD. Therefore, it was impossible to accurately evaluate the binding activity and binding stability of the target molecule with the natural PKCδ protein, and it was difficult to standardize the quality control and optimization of the performance of the targeting reagent.
[0006] 4. A standardized quality control and preservation system that can be industrialized has not been established: The paper only focuses on basic laboratory mechanism research, without establishing quality control standards for the purity and potency of specific antibodies, lacking product parameters such as buffer formulations, concentrations, and volumes suitable for long-term storage, and failing to provide standardized biological reagent product solutions that are reusable and mass-producible. This makes it impossible to support the industrialization of clinical diagnostic kits and targeted therapy candidate drugs. Furthermore, it only validates the value of the PKCδ target alone, without expanding into a multi-scenario application system, and cannot simultaneously meet the multi-dimensional needs of basic scientific research, clinical in vitro diagnostics, and in vivo disease intervention.
[0007] In summary, existing preliminary papers have only completed the scientific value verification of the PKCδ target, lacking highly specific and high-affinity anti-human PKCδ monoclonal antibodies, hybridoma cell lines that stably secrete antibodies, complete antibody preparation processes, quantitative affinity detection methods, and supporting product quality control systems. This limits the transformation of the PKCδ target from basic laboratory research to clinical diagnostic and disease treatment products. Summary of the Invention
[0008] Purpose of the invention: To provide a more effective monoclonal antibody 7G7F9 against human protein kinase CPKC, as well as nucleic acids, cell lines, vectors, their uses, and preparation methods. Specific objectives are detailed in the specific implementation section, which outlines several substantial technical effects.
[0009] 4G7G5 is a highly specific monoclonal antibody against human / mouse protein kinase C-δ (PKCδ), and 7G7F9 is a highly specific monoclonal antibody against human protein kinase C-δ (PKCδ).
[0010] This invention fully discloses the complete variable region gene sequence of the 4G7G5 monoclonal antibody, supporting genetic engineering modification, humanized antibody development, and recombinant antigen preparation for AD diagnostic kits, thus constructing a complete industrial gene resource chain from hybridoma cells to recombinant antibodies. This invention also fully discloses the complete variable region protein sequence of the 7G7F9 monoclonal antibody, providing a theoretical basis for antibody storage formulation optimization, in vivo drug delivery development, and AD targeted therapy drug research and development, thus establishing a complete link from basic sequence analysis to disease intervention product transformation.
[0011] The variable region amino acid sequences of the two antibodies (4G7G5 and 7G7F9) are completely unique, representing novel and original targeting molecules for this invention. No identical sequences have been disclosed in existing technologies, demonstrating outstanding novelty and inventiveness, making them suitable as core targets for patent protection. The two antibodies (4G7G5 and 7G7F9) can be applied in multiple scenarios: preparing diagnostic kits for Alzheimer's disease to achieve quantitative target detection, developing targeted monoclonal antibody drugs to intervene in neuroinflammation, and serving as research tool proteins, thus establishing a complete industrialization chain from cellular raw materials to therapeutic products.
[0012] To achieve the above objectives, the present invention adopts the following technical solution: Option 1: Monoclonal antibody 4G7G5 against human protein kinase CPKC, nucleic acid, cell line, vector, and their uses and preparation methods; Option 2: Monoclonal antibody 7G7F9 against human protein kinase CPKC, nucleic acid, cell line, vector, and their uses and preparation methods; Option 1: Monoclonal antibody 4G7G5 against human protein kinase CPKC, nucleic acid, cell line, vector, and their uses and preparation methods; A monoclonal antibody 4G7G5 against human protein kinase CPKC, wherein the monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence, characterized in that: The amino acid sequence of the heavy chain variable region is evqleqsgaelvkpgasvklsckasgftftsyylywvkqrpgqglewigginpnnggtnfnekfkskatltvdkssstaymqlssltsedsavyycasdgsdywgqgttltvss; The amino acid sequence of the light chain variable region is divmtqtplslpvslgdqasiscrssqsivhsngntylewylqkpgqspklliykvskrfsgvpdrfrgsgsgtdftlkisrveaedlgvyycfqgshfpytfgggtkleik.
[0013] A further technical solution of the present invention is that the dissociation constant (KD) between the monoclonal antibody and the PKC protein is 2.26 × 10⁻ 9 M, the binding rate constant (Ka) is 1.50 × 10⁻⁶. 5 The dissociation rate constant (Kd) is 3.39 × 10⁻ / Ms. 4 1 / s; the purity of the monoclonal antibody was ≥90% as determined by SDS-PAGE electrophoresis; the titer of the monoclonal antibody against human PKC / PKCδ protein was ≥1093.5K as determined by indirect ELISA; the monoclonal antibody was preserved in a buffer solution containing PBS pH7.4 + 1% sucrose + 0.05‰ preservative, with a concentration of 0.95 mg / mL and a volume of 2.0 mL.
[0014] 3. A nucleic acid molecule encoding the heavy chain variable region and / or the light chain variable region of the monoclonal antibody 4G7G5, characterized in that: the nucleic acid sequence of the heavy chain variable region is gaggttcagctggagcagtctggggctgaactggtgaagcctggggcttcagtgaagttgtcctgcaaggcttctggcttcaccttcaccagctactatctgtactgggtgaagcagaggcctggacaaggccttgagtggattggggggattaatcctaacaatggtggtactaacttcaatgagaaattcaagagcaaggccacactgactgtagacaaatcctccagcacagcctacatgcaactcagcagcctgacatctgaggactctgcggtctattactgtgcaagtgatggctctgactactggggccaaggcaccactctcacagtctcctca; The nucleic acid sequence of the light chain variable region is gacattgtgatgacccaaactccactctccctgcctgtcagtcttggagatcaagcctccatctcttgcagatctagtcagagcattgtacatagtaatggaaacacctatttagaatggtacctgcagaaaccaggccagtctccaaagctcctgatctac aaagtttccaagcgattttctggggtcccagacaggttcagaggcagtggatcagggaccgatttcacactcaagatcagtagagtggaggctgaggatctgggagttattactgctttcaaggttcacattttccgtacacgttcggaggggggacaaagctggaaataaaa.
[0015] A recombinant expression vector, characterized in that: the vector contains nucleic acid molecules as described above.
[0016] A recombinant host cell, characterized in that: the host cell expresses the monoclonal antibody 4G7G5 as described above, and the host cell is selected from mammalian cells, yeast cells or Escherichia coli cells.
[0017] A hybridoma cell line, characterized in that: the hybridoma cell line can secrete the monoclonal antibody 4G7G5 as described above, and the hybridoma cell line was deposited at the China Committee for Type Culture Collection (CCTCC) on June 11, 2026, with accession number CCTCC NO:C202683.
[0018] The application of the monoclonal antibody 4G7G5, the nucleic acid molecule of the heavy chain variable region and / or light chain variable region of the monoclonal antibody 4G7G5, the recombinant expression vector, the recombinant host cell, and the hybridoma cell line in the preparation of diagnostic reagents or diagnostic kits for detecting human PKC protein.
[0019] The use of the monoclonal antibody 4G7G5, the nucleic acid molecule of the heavy chain variable region and / or light chain variable region of the monoclonal antibody 4G7G5, the recombinant expression vector, the recombinant host cell, and the hybridoma cell line in the preparation of drugs for the treatment of Alzheimer's disease (AD) or neuroinflammatory-related diseases.
[0020] A diagnostic kit, characterized in that: the diagnostic kit contains the monoclonal antibody 4G7G5 as described above.
[0021] A method for preparing a monoclonal antibody 4G7G5 against human protein kinase CPKC, characterized by comprising the following steps: Phase 1 (M1): Animal immunization and antiserum titer assessment: Antiserum is prepared from animals immunized with antigens, the antiserum titer is assessed, and a GO / NO-GO decision is made; Phase Two (M2) Cell Fusion Screening Phase: Cell fusion to obtain antigen-specific fusion cell lines; Phase 3 (M3): Cell subcloning and line determination: Cell subcloning obtains single-clone cell lines specific to the antigen; Phase 4 (M4): Antibody expression and purification phase: Antibody purification yields more than 1 mg of specific antibody.
[0022] Option 2: Monoclonal antibody 7G7F9 against human protein kinase CPKC, nucleic acid, cell line, vector, and their uses and preparation methods; A monoclonal antibody 7G7F9 of human protein kinase CPKC, wherein the monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence, characterized in that: The amino acid sequence of the heavy chain variable region is qvqleqsggdlvkpggslklscaasgftfsnyamswirltpekklewvatistassytyysdsvkgrftisrdnvkntlylqmsslrsedtaiyycarqgttvvdfdywgqgttltvss; The amino acid sequence of the light chain variable region is divltqspsslsaslgdrvtiscrasqdisnylnwyqqkadgtvklliyyisrlhsgvpsrfsgsgsgtdfsltitnleqediatyfcqqgnslpwtfgggtklelk.
[0023] A further technical solution of the present invention is that the dissociation constant (KD) between the monoclonal antibody and the PKC protein is 8.57 × 10⁻ 9 M, the binding rate constant (Ka) is 8.10 × 10⁻⁶. 4 1 / Ms, the dissociation rate constant (Kd) is 6.94 × 10⁻ 4 1 / s; the purity of the monoclonal antibody was ≥90% as determined by SDS-PAGE electrophoresis; the titer of the monoclonal antibody against human PKC / PKCδ protein was ≥1093.5K as determined by indirect ELISA; the monoclonal antibody was preserved in a buffer solution containing PBS pH 7.4 + 1% sucrose + 0.05‰ preservative, with a concentration of 1.00 mg / mL and a volume of 2.0 mL.
[0024] A nucleic acid molecule encoding the heavy chain variable region and / or the light chain variable region of the monoclonal antibody 7G7F9, characterized in that: the nucleic acid sequence of the heavy chain variable region is caggtccagctggagcagtctgggggagacttagtgaagcctggagggtccctgaaactctcctgtgcagcctctggattcactttcagtaactatgccatgtcttggattcgcctgactccggagaagaagctggagagtgggtcgcaaccattagtactgctagtagttacacctactattcagacagtgtgaaggggcgattcaccatctccagagacaatgtcaagaacaccctgtacctacaaatgagcagtctgaggtctgaggacacggccatatattactgtgcaagacaggggactacggtagtggtgaggcaccatctccagagacaatgtcaagaacaccctgtgatacaaatgagcagtctgaggtctgaggacacggccatatattactgtgcaagacaggggactacggtagtggactttgactactggggccaaggcaccactctcacagtctcctca; The nucleic acid sequence of the light chain variable region is gacattgtgctcacccagtctccatcatccctgtctgcctctctggggagacagtcaccatcagttgcagggcaagtcaggacattagcaattatttaaactggtatcagcagaaagcagatggaactgttaaactcctgatctactacatatc aagattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagatttttctctcaccattaccaacttggaacaagaagatattgccacttacttttgccaacagggtaattcgcttccgtggacgttcggtggaggcaccaagctagaactcaaa.
[0025] A recombinant expression vector, characterized in that: the vector contains nucleic acid molecules as described above.
[0026] A recombinant host cell, characterized in that: the host cell expresses the monoclonal antibody 7G7F9, and the host cell is selected from mammalian cells, yeast cells or Escherichia coli cells.
[0027] A hybridoma cell line, characterized in that: the hybridoma cell line can secrete the monoclonal antibody 7G7F9 as described above, and the hybridoma cell line was deposited at the China Committee for Type Culture Collection (CCTCC) on June 11, 2026, with accession number CCTCC NO:C202684.
[0028] The use of the monoclonal antibody 7G7F9 as described above, the nucleic acid molecule of the heavy chain variable region and / or light chain variable region of the monoclonal antibody 7G7F9 as described above, the recombinant expression vector as described above, the recombinant host cell as described above, and the hybridoma cell line as described above in the preparation of diagnostic reagents or diagnostic kits for detecting human PKC protein.
[0029] The use of the monoclonal antibody 7G7F9 as described above, the nucleic acid molecule of the heavy chain variable region and / or light chain variable region of the monoclonal antibody 7G7F9 as described above, the recombinant expression vector, the recombinant host cell, and the hybridoma cell line in the preparation of a drug for treating Alzheimer's disease (AD) or neuroinflammatory-related diseases.
[0030] A diagnostic kit, characterized in that: the diagnostic kit contains the monoclonal antibody 7G7F9.
[0031] A method for preparing a monoclonal antibody 7G7F9 against human protein kinase CPKC, characterized by comprising the following steps: Phase 1 (M1): Animal immunization and antiserum titer assessment: Antiserum is prepared from animals immunized with antigens, the antiserum titer is assessed, and a GO / NO-GO decision is made; Phase Two (M2) Cell Fusion Screening Phase: Cell fusion to obtain antigen-specific fusion cell lines; Phase 3 (M3): Cell subcloning and line determination: Cell subcloning obtains single-clone cell lines specific to the antigen; Phase 4 (M4): Antibody expression and purification phase: Antibody purification yields more than 1 mg of specific antibody.
[0032] The present invention, employing the above technical solution, offers the following advantages over existing technologies: It pioneered two specific anti-human PKCδ hybridoma cell lines, 4G7G5 and 7G7F9, and completed CCTCC preservation, disclosing complete light and heavy chain variable region nucleic acid and amino acid sequences. This provides original gene and cell resources for the independent preparation of targeted antibodies, avoiding reliance on commercial reagents. A standardized four-stage monoclonal antibody preparation process was established, yielding antibodies with a purity ≥90% after Protein G affinity purification. A single batch can stably produce 1.9 mg and 2.0 mg of high-purity antibodies, accompanied by a dedicated long-acting preservation buffer, suitable for large-scale mass production. SPR technology was introduced to quantitatively characterize antigen-antibody interactions, accurately measuring sub-nanomolar affinity parameters. 4G7G5 exhibits superior affinity compared to 7G7F9, filling the gap in traditional ELISA's qualitative but non-quantitative approach to binding kinetics, and establishing a unified standard for antibody performance evaluation. With high antibody specificity, no off-target defects of chemical inhibitors, and a titer exceeding 1093.5K, it can be applied in multiple scenarios: preparing Alzheimer's disease diagnostic kits to achieve quantitative detection of targets, developing targeted monoclonal antibody drugs to intervene in neuroinflammation, and also serving as a research tool protein, thus opening up a complete industrialization chain from cellular raw materials to diagnostic and therapeutic products. Attached Figure Description
[0033] To further illustrate the present invention, the following description is provided in conjunction with the accompanying drawings: Figure 1. SDS-PAGE electrophoresis analysis of purified antibodies; where: M: protein molecular weight standard; 1: 4G7G5 antibody purification analysis results; 2: 7G7F9 antibody purification analysis results; Figure 2 and Figure 3 The principle of SPR experiment; Figure 4 shows the interaction determination between PKC and 4G7G5; Figure 5 The interaction between PKC and 7G7F9 was determined; Figure 6 The nucleic acid sequence is the 4G7G5 heavy strand variable region; Figure 7 The nucleic acid sequence is the 4G7G5 light chain variable region; Figure 8 The nucleic acid sequence is the 7G7F9 heavy chain variable region; Figure 9 The nucleic acid sequence is the 7G7F9 light chain variable region; Figures 6 to 9In the image, 4G7G5 represents the antibody clone number. ChainType indicates whether it's a heavy or light chain. VH = Variable Heavy, heavy chain variable region; VL = Variable Light, light chain variable region; Kabat indicates the use of the Kabat antibody numbering rule, the most classic antibody sequence partitioning standard, used to define FR and CDR boundaries. FR1-Kabat / FR2-Kabat / FR3-Kabat / FR4-Kabat; FR = Framework Region, the relatively conserved backbone sequence of the antibody variable region, maintaining the protein's three-dimensional folding structure. The four FRs separate the three CDRs. CDR1-Kabat / CDR2-Kabat / CDR3-Kabat; CDR stands for Complementarity-Determining Region, which is a highly variable region where antibodies and antigens directly bind, determining antibody specificity. CDR3 exhibits the highest diversity. The fixed arrangement order of antibody variable regions is: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0034] Preservation Information 1: China Center for Type Culture Collection; Address: Wuhan University, Wuhan, China; Applicant: Zhang Wei; Accession Number: CCTCC NO: C202683; Culture Name: Hybridoma cellline 4G7G5; This culture was received and registered by the Center on May 12, 2026, and will be preserved for thirty years from the date of receipt. A five-year extension may be granted upon request for samples submitted before the expiry date; Viability Test: Viability testing was completed on May 22, 2026, and the result was positive; The certificate of preservation was issued on June 11, 2026.
[0035] Preservation Information 2: China Center for Type Culture Collection; Address: Wuhan University, Wuhan, China; Applicant: Zhang Wei; Accession Number: CCTCC NO: C202684; Culture Name: Hybridoma cellline 7G7F9; Registration: This culture was received and registered by the Center on May 12, 2026, and will be preserved for thirty years from the date of receipt. A five-year extension may be granted upon request for samples submitted before the expiry date; Viability Test: Viability testing was completed on May 22, 2026, and the result was positive; Certificate of Preservation Issuance Date: June 11, 2026.
[0036] Figure 1 To illustrate the results of reduced SDS-PAGE protein electrophoresis, M represents the protein molecular weight marker. Lane 1 corresponds to the purified antibody 4G7G5, and lane 2 corresponds to the purified antibody 7G7F9. The electrophoretic bands clearly show two characteristic bands, matching the standard molecular weights of the 55KD antibody heavy chain and 25KD antibody light chain, respectively. There are no obvious diffuse bands or extraneous bands interfering with the results. This figure visually demonstrates that the supernatant from the hybridomas 4G7G5 and 7G7F9, after affinity purification with Protein G, yielded complete IgG-type monoclonal antibodies. This strongly proves that the two antibody preparation and purification processes are stable and reliable, with antibody purity ≥90%. A standardized antibody quality control and identification method has been established, overcoming the deficiency of existing technologies lacking large-scale purification quality control standards. This provides high-purity, qualified antibody raw materials for subsequent SPR affinity detection, ELISA kit development, and in vivo drug experiments.
[0037] Figure 2 This paper fully demonstrates the optical detection system of the Biacore SPR device, including the incident light source, prism, 50nm gold film dextran sensor chip, buffer flow path, and reflected light detector. It also simultaneously labels the correlation curves between SPR resonance angle shift and reflected light energy and detection time, comprehensively elucidating the underlying optical mechanism of label-free SPR molecular interaction detection. This figure clearly demonstrates that the antigen-antibody affinity quantification method used in this patent has solid physical and optical theoretical support; it strongly proves the scientific rationality of the innovative introduction of the SPR quantitative characterization system in this invention, filling the technical gap of traditional research relying solely on ELISA for qualitative analysis and unable to quantify antigen-antibody binding kinetic parameters. This provides theoretical evidence at the principle level for the sensor curve data in Figures 4 and 5.
[0038] Figure 3 The SPR chip surface molecular reaction process is illustrated in three steps: First, the ligand Ligand (PKC protein) is immobilized on the chip's dextran matrix; second, the mobile phase analyte (monoclonal antibody) specifically binds to the immobilized ligand, resulting in a continuous increase in the response value; third, after rinsing with buffer, the complex dissociates, and the signal returns to the baseline, with a corresponding complete kinetic sensing curve below. This figure demonstrates step-by-step that the PKC protein and the 4G7G5 / 7G7F9 monoclonal antibody exhibit reversible and specific binding and dissociation molecular interactions in the SPR experiment; it strongly proves that the SPR experimental design of this patent is logically rigorous, capable of capturing the entire dynamic interaction process of antigen and antibody in real time, and accurately extracting three core affinity quantitative parameters: Ka binding rate, Kd dissociation rate, and KD equilibrium dissociation constant, establishing a unified and reusable standard for evaluating the performance of targeted antibodies.
[0039] Figure 4The real-time response curves of 4G7G5 antibody flowing through a fixed PKC protein chip at concentration gradients from 0.3125 nM to 10 nM are shown. All concentration curves exhibit a typical kinetic pattern of "rapid binding rise - equilibrium plateau - slow dissociation decline," and the higher the antibody concentration, the higher the RU response peak during the equilibrium phase. The gradient stratification is clear and without cross-contamination. This figure visually demonstrates that the 4G7G5 antibody can specifically bind to native conformation human PKC protein in a concentration-dependent manner, with reversible molecular binding and stable binding activity. This strongly proves that 4G7G5 is a high-affinity, specific monoclonal antibody targeting PKC. The binding kinetic curve fitting yields a KD of 2.26 × 10⁻⁻⁻⁶. 9 M, with its sub-nanomolar affinity data, is highly reliable and has significant advantages over traditional pan-PKC inhibitors in terms of precise targeting and strong binding.
[0040] Figure 5 The SPR sensing curves for the interaction between 7G7F9 antibody and immobilized PKC protein at gradient concentrations ranging from 0.3125 nM to 10 nM are shown. The curve trend conforms to the standard 1:1 Langmuir binding model, with the equilibrium RU peak increasing synchronously with increasing antibody concentration. The signal changes during the binding and dissociation phases are smooth, without baseline drift caused by non-specific adsorption. This figure clearly demonstrates that the 7G7F9 antibody can also specifically recognize natural human PKC protein and possesses concentration-dependent reversible binding characteristics; it strongly proves that 7G7F9 is a highly specific anti-PKC monoclonal antibody with a KD of 8.57 × 10⁻⁻⁻⁶. 9 M, compared with Figure 4, can intuitively distinguish the affinity of the two antibodies (4G7G5 has a better affinity than 7G7F9), realize the objective quantitative benchmarking of the performance of different target antibodies, and improve the screening and evaluation system of multiple candidate antibodies of this invention.
[0041] Figure 6 Following the classic Kabat antibody numbering rules, the 4G7G5 heavy chain variable region nucleic acid sequence is completely dissected into seven functional regions: FR1 / CDR1 / FR2 / CDR2 / FR3 / CDR3 / FR4. The complete base sequence of the full-length variable region is also provided, clearly distinguishing the conserved backbone region FR and the hypervariable antigen-binding region CDR. This figure fully demonstrates the coding nucleic acid sequence and functional region boundaries of the 4G7G5 heavy chain variable region, clearly identifying CDR1 / CDR2 / CDR3 as the core coding regions for antigen recognition. This strongly demonstrates that this invention discloses for the first time the molecular genetic basis of 4G7G5 antibody specificity, which can be directly used to construct recombinant expression vectors and engineered host cells to achieve in vitro recombinant antibody expression, overcoming the shortcomings of existing technologies that lack independent antibody gene resources and rely on commercial reagents.
[0042] Figure 7 Using the same Kabat partitioning standard as Figure 6, the nucleic acid sequences of each FR and CDR in the variable region of the 4G7G5 light chain, as well as the full-length complete sequence, are displayed segment by segment, distinguishing between the conserved light chain backbone sequence and the highly variable CDR segment responsible for antigen binding. This figure accurately demonstrates that the entire 4G7G5 light chain variable region encodes nucleic acid information, which, combined with the heavy chain sequence in Figure 6, constitutes a complete antigen recognition Fv domain; it strongly proves that this invention fully discloses the complete set of variable region genes of the 4G7G5 monoclonal antibody, which can support genetic engineering modification, humanized antibody development, and recombinant antigen preparation for diagnostic kits, constructing a complete industrial gene resource chain from hybridoma cells to recombinant antibodies.
[0043] Figure 8 Based on the Kabat rule, the amino acid sequence of the 7G7F9 heavy chain variable region is divided into FR and CDR functional regions, fully displaying the amino acid residue arrangement of each segment and the full-length variable region protein sequence. The figure visually presents the characteristic amino acid sequence of the CDR, which determines antibody binding specificity. This figure directly demonstrates the primary structure of the 7G7F9 heavy chain variable region protein, clearly showing that the CDR amino acid residues are the key structural basis for mediating PKC antigen-specific recognition. It strongly proves that the amino acid sequences of the variable regions of the two antibodies (4G7G5 and 7G7F9) are completely unique, representing novel and original targeting molecules for this invention. No identical sequences are disclosed in existing technologies, demonstrating outstanding novelty and inventiveness, and making them a core target for patent protection.
[0044] Figure 9 Figure 8, accompanying the diagram, shows the amino acid sequence of the 7G7F9 light chain variable region, broken down according to the Kabat standard. It clearly marks four conserved frame regions (FRs) and three highly variable CDR complementarity-determining regions (CDRs), providing the complete full-length amino acid sequence of the light chain. This figure fully demonstrates the primary structure of the 7G7F9 light chain variable region protein, which, together with the heavy chain sequence in Figure 8, forms a complete antigen-binding pocket. This strongly demonstrates that the present invention fully discloses the complete variable region protein sequence of the 7G7F9 monoclonal antibody, explaining the molecular structural basis for the differences in affinity and specificity between the two antibodies. Simultaneously, it provides a theoretical basis for antibody storage formulation optimization, in vivo drug delivery development, and AD targeted therapy drug research, establishing a complete link from basic sequence resolution to disease intervention product transformation. Detailed Implementation
[0045] The present invention will be further illustrated below with reference to the accompanying drawings and specific embodiments. It should be understood that the following specific embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.
[0046] Phase 1 (M1): Assessment of animal immunity and antiserum titers Project Objectives Antiserum was prepared by immunizing animals with antigens, the antiserum titer was evaluated, and a GO / NO-GO decision was made.
[0047] Experimental materials and main instruments Experimental subjects
[0048] Experimental methods and operating procedures Animal Immunization Immunization schedule: Immunize 5 BALB / c mice with a subcutaneous immunization of 100 μg per mouse for the first time, followed by immunization 2-3 weeks later. One dose, 50 μg / dose, for 4 immunizations. The specific immunization procedure is as follows:
[0049] Antiserum titer testing The antiserum titer was detected by indirect ELISA. The indirect ELISA procedure is as follows: Dilute the antigen to the required concentration using coating buffer, mix well, and add 100 μL to each well of a 96-well plate. Incubate overnight at 4°C.
[0050] Coating antigens: human PKC, mouse PKC delta protein, mouse PKC delta protein Coating concentration: 1 μg / mL, 100 μL / well Coating buffer: Phosphate-buffered saline (PBS, pH 7.4) Remove the 96-well plate, discard the coating solution, wash the plate three times with PBST, and add 200 μL of blocking buffer to each well. Incubate at 37°C for 1 hour. Remove the 96-well plate, discard the blocking solution, and wash the plate once.
[0051] The antiserum was diluted 3 times at a ratio of 1:500, with 100 μL per well, and incubated at 37°C for 1 h.
[0052] Remove the 96-well plate, discard the solution in the wells, wash the plate three times, and add 100 μL of diluted enzyme to each well. Incubate with secondary antibody (enzyme-labeled secondary antibody preparation: goat anti-mouse-HRP, 1:20,000) at 37°C for 1 h.
[0053] Remove the 96-well plate, discard the solution in the wells, wash the plate 4 times, add 100 μL of TMB colorimetric solution to each well, and incubate at 37 ℃ for 15 min.
[0054] Add 100 μL of 1 M HCl solution to each well to stop the reaction. Immediately label the wells with a microplate reader at 450 nm. The maximum dilution factor of the antiserum corresponding to the well with an OD value greater than 2.1 times the set negative control OD value is defined as the titer of the sample.
[0055] Experimental results The results of the antiserum titer test after the fourth immunization are as follows: Five BALB / c mice were immunized in this project, and a good immune response was achieved after four immunizations. The results of indirect ELISA screening of mouse serum seven days post-immunization are shown in the table below.
[0056]
[0057] Phase Two (M2): Cell Fusion Screening Phase Project Objectives Cell fusion yields antigen-specific fusion cell lines.
[0058] Experimental materials and main instruments experimental cells
[0059] Experimental methods and operating procedures Cell electrofusion Preparation of myeloma cells One week prior to fusion, SP2 / 0 cells were expanded in DMEM medium containing 10% FBS. By fusion, the cells had filled approximately six T25 cell culture flasks. On the day of fusion, SP2 / 0 cells were collected into 50 mL centrifuge tubes and centrifuged at 1500 rpm for 5 min. The supernatant was discarded, and then 20 mL of DMEM basal medium was added. The cells were dispersed and counted.
[0060] Spleen cell preparation Mice whose serum ELISA titers met the order requirements after immunization underwent cell fusion. Three days prior to fusion, mice were terminally immunized and injected intraperitoneally with 100 μg of antigen. On the day of fusion, the mice to be fused were euthanized by cervical dislocation. The cells were soaked in 75% alcohol for 5 minutes. The spleen was aseptically harvested and placed in a culture dish containing 10 mL of DMEM basal culture. A sieve was placed in another petri dish, and the spleen was transferred to the sieve. The spleen was then ground using the inside of a syringe. DMEM was added to the sieve, and the sieve was rinsed to collect more spleen cells into the petri dish. The cells were transferred to 50 mL centrifuge tubes, washed once with serum-free DMEM, and centrifuged at 1500 rpm for 5 minutes. The spleen cells were collected, and red blood cells were removed with erythrocyte lysis buffer. The spleen cells were washed once with serum-free DMEM and centrifuged at 1500 rpm for 5 minutes. The spleen cells were collected and counted.
[0061] Cell fusion Myeloma cells and spleen cells were mixed to achieve an appropriate ratio. Cells were transferred to 50 mL centrifuge tubes, diluted with DMEM basal medium, and centrifuged at 1500 rpm for 5 min. The supernatant was discarded. The centrifuge tubes were shaken to homogenize the cells, washed once with electrofusion buffer, and then centrifuged at 1500 rpm for 5 min. The supernatant was discarded. Cells were diluted to 2 × 10⁷ cells / mL with electrofusion buffer, and 2 mL of cell suspension was added to the fusion chamber for electrofusion experiments. After electrofusion, the cells were allowed to stand for 10 min. Then, HAT DMEM medium was added. The fused cells were seeded into 96-well plates, 100 μL per well. The cell culture plates were then incubated in a CO₂ incubator. Cells were checked 6 days after fusion, and screening was performed 10 days after fusion.
[0062] Cell fusion screening The day before the test, 1 μg / mL antigen was coated onto an ELISA plate with PBS and incubated overnight. The next day, 100 μL of cell supernatant was aspirated per well for ELISA detection. Based on the ELISA results, positive wells were identified (wells with an OD value of ≥2.1 between the sample well and the negative well were considered positive). Positive wells were picked using a single-channel pipette for a second confirmatory test to further confirm their positive status. Cells from the confirmed positive wells were then subcloned.
[0063] Experimental results The cell fusion screening results are as follows: Indirect ELISA was used to detect antibodies that specifically bind to antigens in cell supernatants. The conditions are as follows: The results are shown in the indirect ELISA screening results table of the fusion cell supernatant. Through indirect ELISA screening of cell supernatant, 10 cell lines (1F6, 3G4, 4F9, 4G7, 5F7, 7G7, 8F4, 9F8, 10F3, 10F9) were obtained, and 4 cell lines (1F10, 2B3, 2D10, 3F9) were obtained that were reactive only to human PKC / human PKC delta protein. Subcloning experiments were then performed on the obtained cell lines.
[0064] Phase 3 (M3): Cell subcloning and prototyping stage Project Objectives Cell subcloning yields single-clone cell lines specific to antigens.
[0065] Experimental materials and main instruments Main reagents
[0066] Experimental methods and operating procedures Cell subcloning experiment Pipe the cells in the positive wells and count them. Add N / 4 mL of DMEM medium (N is the cell count result) to a centrifuge tube. Take 100 μL of cell suspension into the centrifuge tube, mix well, and leave 1 mL. Add DMEM to 4 mL, mix well, and leave 100 μL (about 2 drops) at the bottom of the tube. Add DMEM to 5 mL in a centrifuge tube, mix well, and then add it dropwise to the first three wells of a 96-well plate, leaving about 1.8-2 mL at the bottom of each well. Add DMEM to 5 mL, mix well, and then add it dropwise to the D, E, and F wells of the 96-well plate, leaving about 1.5-1.8 mL at the bottom of each well. Add DMEM to 2.8-3 mL, mix well, and then add it dropwise to the G and H wells of the 96-well plate, leaving about 1.5-1.8 mL at the bottom of each well. After 7-10 days, observe under a microscope and check the wells with clonal growth. Mark the wells with single clones. Pick as many positive single clones as possible for subcloning. After 100% positivity, pick the single clone wells for expansion culture and establishment.
[0067] Cell subcloning screening detection The day before the test, 1 μg / mL antigen was coated onto an ELISA plate with PBS and incubated overnight. The next day, 100 μL of cell supernatant was aspirated per well for ELISA detection. Based on the ELISA results, positive wells were identified (wells with an OD value of ≥2.1 between the sample well and the negative well were considered positive). Positive wells were picked using a single-channel pipette for a second confirmatory test to further confirm their positive status. Cells from the confirmed positive wells were then subcloned.
[0068] Experimental results The results of cell subcloning screening are as follows: Indirect ELISA was used to detect antibodies specifically binding to antigens in cell supernatants. Specific results are shown in the subclonal cell supernatant indirect ELISA screening results table. Through indirect ELISA screening of cell supernatants, 5 cell lines reactive to human PKC / human PKC delta protein / mouse PKC delta protein were obtained (3G4H 11, 4G7G5, 7G7F12, 8F4H4, 10F3E9), and 5 cell lines reactive only to human PKC / human PKC delta protein were obtained (1F 10E 11, ...). D 10G6, 5F7F4, 7G7F9, 7G7G5), and at the same time, the obtained cell lines were cryopreserved for seed preservation.
[0069] Phase 4 (M4): Antibody Expression and Purification Phase Project Objectives Antibody purification yielded more than 1 mg of specific antibody.
[0070] Experimental materials and main instruments Main reagents
[0071] Antibody expression Cell expansion was performed using 4G7G5 and 7G7F9 monoclonal cell lines, and antibodies were expressed in serum-free cell culture.
[0072] Antibody purification and identification Antibody purification Protein G agarose gel medium was loaded into an affinity purification chromatography column, and the cell expression supernatant was slowly loaded. After the antibody bound, it was eluted with glycine elution buffer to obtain the desired purified antibody. The antibody was then immediately dialyzed overnight in PBS at 4°C.
[0073] Purified antibody identification Antibody titer was detected by indirect ELISA, antibody concentration was determined using a BCA concentration assay kit, and antibody purity was identified by SDS-PAGE electrophoresis.
[0074] Purified antibody ELISA titer assay The purified antibody titer was determined using indirect ELISA.
[0075] Experimental results Antibody purity identification results The purified antibody was subjected to SDS-PAGE electrophoresis and stained with Coomassie Brilliant Blue. The antibody purity was above 90%, as shown in Figure 1.
[0076] Antibody purification yielded 7387 Specific antibodies were obtained through antibody expression, and the results are shown in the table.
[0077]
[0078] Antibody indirect ELISA detection results Based on ELISA titer assay results, the purified 4G7G5 antibody targets human PKC / human PKC delta protein. The titers of all antibodies reached 1093.5 K, with the 4G7G5 purified antibody reaching approximately 121.5 K against murine PKC delta protein. The 7G7F9 purified antibody also reached approximately 1093.5 K against both human and human PKC delta proteins, while the 7G7F9 purified antibody reached approximately 1.5 K against murine PKC delta protein. See the antibody indirect ELISA screening results table for detailed results.
[0079] Experimental conclusions The project successfully obtained two monoclonal cell lines of antibodies specific to the antigen. These antibodies were expressed and purified. 1.9 mg of purified antibody was obtained from 4G7G5 and 2.0 mg of purified antibody was obtained from 7G7F9.
[0080] SPR Testing Experiment Report I. Main Experimental Instruments and Consumables instrument:
[0081] Figure 2 The Biacore system, based on surface plasmon resonance (SPR) technology, records in real time changes in the molecular mass on the surface of a sensor chip during molecular binding and dissociation, thereby monitoring intermolecular interactions in real time. To study the interaction between two molecules, one molecule is fixed to the chip surface (Ligand), while the other molecule (analyte) flows continuously across the chip surface in solution form. The detector can detect the binding and dissociation processes of molecules in the solution with those on the chip surface in real time and display them as SPR response values.
[0082] Under total internal reflection, the incident light causes the thin gold layer plasma to resonate, resulting in the reflected light having energy as low as almost zero at a certain angle (SPR angle); SPR is highly sensitive to changes in refractive index in the 100-200 nm range for gold film solutions. The reversible binding / dissociation between molecules causes real-time changes in the refractive index near the gold film; this phenomenon is... Biacore records in real time.
[0083] Biacore is similar to a high-precision optical balance. It amplifies signals through the SPR principle and can detect material changes of 1 pg / mm2 on the chip surface.
[0084] refer to Figure 3 After the protein amino group is coupled to the chip, the analyte small molecule is injected onto the chip surface and binds to the protein, generating a binding signal. After the injection is stopped, the small molecule dissociates from the chip, and the signal returns to the baseline. Three Experimental Procedures Experimental samples Protein samples:
[0085] Experimental methods The proposed method is amino coupling for protein fixation. Protein-coupled buffer solution: 1.0×PBS-P+ (pH 7.4); Interaction buffer solution: 1.0×PBS-P+ (pH 7.4), 5% (v / v) DMSO 3.2.1 Protein Coupling Place the running buffer (200 mL 1×PBS Buffer), water bottle, and waste bottle in the left and right trays respectively, and insert the corresponding inlet tubes.
[0086] Hold the CM5 chip with the printed side facing up. Gently push the chip into the slot following the arrow on the chip, and finally close the chip compartment door.
[0087] Channel 2 of the chip was activated at a flow rate of 10 μL / min using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Cytiva) and N-hydroxysuccinimide (NHS, Cytiva).
[0088] The ligand protein was diluted with sodium acetate to 50 μg / mL and immobilized in channel 2 of the chip at a flow rate of 10 μL / min to generate a coupling map.
[0089] The channel was sealed with ethanolamine at a flow rate of 10 μL / min.
[0090] 3.3.2 PKC protein-analyte interaction test Solvent correction: The run buffer for the analyte is 1×PBS-P+ containing 5% DMSO. Replace the original run buffer in the left tray of the system with 1×PBS-P+ containing 5% DMSO and insert the corresponding inlet tube. Prepare the 5% DMSO concentration calibration curve by mixing 4.5% and 5.8% stock solutions according to the table below:
[0091] Analyzing the substance: Each analyte was diluted to several concentrations in a 96-well plate and coupled to the target protein via a chip from low to high concentration. The flow rate was 30 μL / min, and the duration was 360 s.
[0092] After each concentration point was passed, the chip was regenerated using a 10 mM glycine hydrochloride (pH 2.0) solution. min, repeat this process until all the corresponding concentrations of the analytes have been measured.
[0093] (3) The data was evaluated using Biacore Insight software (Cytiva, Marlborough, MA, USA). By globally fitting to a 1:1 Langmuir binding model, the binding and dissociation constants are obtained.
[0094] IV. Experimental Results and Data Analysis; The analytes were determined according to their solubility concentration, and the kinetic fitting results of the analytes are as follows: Figure 4 and Figure 5 As shown.
[0095] Five conclusions The purpose of this experiment was to determine the affinity between the analyte and the protein PKC using Biacore, employing a CM5 chip-coupled protein assay. The results are shown in the table below.
[0096]
[0097] The dissociation constant reflects the affinity of the analyte for the target; the smaller the value, the stronger the affinity. Ka: Association rate constant, representing the speed at which molecules bind together; a larger value indicates faster binding. Kd: dissociation rate constant, which represents the speed at which molecules dissociate; a larger value indicates faster dissociation.
[0098] Methods for cell resuscitation culture and cryopreservation experiments: reagents and consumables High-glucose DMEM medium (Zhongding Biotechnology) Fetal bovine serum (Zhongding Biotechnology) Cryopreservation tubes (Zhongding Biotechnology) Culture flasks (purchased from Corning) DMSO (purchased from SIGMA) ELISA strips (purchased from Xiamen Yunpeng Company) All other reagents were domestically produced analytical grade. Experimental instruments Benchtop high-speed centrifuge (SORVAL, Germany) Clean bench (China Sujing Group) AR5120 electronic balance (AHOMS, USA) Rotary culture mixer (Chlimbell Company) ELISA reader (Beijing Pulang Technology) Computerized plate washing machine (Beijing Pulang Technology) μL pipette (Eppendorf) mL pipette (Eppendorf) Experimental methods and results Cell culture Cell resuscitation Determine the location of the cell line to be revived in the liquid nitrogen tank. Remove the frozen cells from the liquid nitrogen or -80°C freezer and quickly place them in a 37°C water bath. Shake continuously to thaw them rapidly, keeping the revival time to about 1 minute. Add the cell suspension to a 15 mL sterile centrifuge tube containing 4 mL of culture medium. Centrifuge at 1000 rpm for 5 minutes. Discard the supernatant, resuspend the pellet, and transfer it to a T25 cm² culture flask for further culture.
[0099] Cell passage When the T25 cm2 culture flask reaches a bottom density of 80-90%, discard the supernatant, gently tap the sides of the culture flask several times, and observe whether the cells detach. Expand the culture by passing the cells at a ratio of 1 to 3.
[0100] Cell cryopreservation Once the cell density reaches 90%, discard the supernatant directly, gently tap the sides of the culture flask several times to collect the cell suspension, centrifuge at 1000 rpm for 5 min, discard the supernatant, resuspend the precipitate in cryopreservation solution, add it to cryopreservation tubes with the cell names written on them, transfer it to a programmed cooling box, and freeze at -80°C overnight. The next day, transfer it to liquid nitrogen for long-term storage (or you can store it at 4°C for 20 min, freeze it completely at -20°C, freeze it at -80°C overnight, and transfer it to liquid nitrogen for long-term storage the next day).
[0101] Cryopreservation solution preparation: 70% FBS + 20% DMEM medium (containing 10% FBS) + 10% DMSO.
[0102] Results Analysis After cell resuscitation and passage culture, the cells grew normally, and the cell line cryopreservation experiment was completed.
[0103] Compared with the shortcomings of existing technologies, this study only uses pan-PKC inhibitors rodttlerin and siRNA for experiments, and lacks specific anti-human PKCδ monoclonal antibodies; rodttlerin has poor target selectivity, serious off-target effects, and insufficient in vivo safety; siRNA is difficult to deliver and has poor stability, and cannot accurately capture and quantify native conformation human PKCδ protein. This patent innovatively and non-obviously combines the entire process of hybridoma monoclonal antibody preparation, the specific hybridoma cell line targeting human PKCδ, and the combined application of two highly specific monoclonal antibodies, 4G7G5 and 7G7F9, and their complete variable region nucleic acid / amino acid sequences, completely overcoming this deficiency and achieving precise identification and quantitative capture of natural human PKCδ. Development of specific targeting tool molecules: Balb / c mouse immunization, cell fusion, and multiple rounds of subclone screening were completed, and two monoclonal antibodies (4G7G5 and 7G7F9) that specifically bind to human PKCδ were finally obtained. The complete nucleic acid and amino acid sequences of their heavy / light chain variable regions were disclosed (Figure 6-9), which are target molecules that have not been disclosed in the existing technology. Overcoming the off-target defects of chemical inhibitors: The monoclonal antibody of this invention specifically binds to human PKCδ protein and does not bind to other PKC family proteins in general. It does not have the off-target toxicity caused by broad-spectrum inhibition of rodentrin and can be safely used for in vivo targeted intervention. Overcoming the instability and delivery limitations of siRNA: The monoclonal antibody of this invention is a stable protein-based targeting reagent that does not require complex vector delivery and has strong stability in liquid formulation; after purification, the antibody can be directly used for quantitative detection of clinical samples by ELISA, accurately capturing native conformation PKCδ protein and overcoming the limitation that siRNA cannot be quantitatively detected in vitro; Validation of target recognition capability: Indirect ELISA confirmed that the titers of both monoclonal antibodies against human PKCδ were ≥1093.5K, and their specificity for recognizing human target proteins was far superior to that of traditional non-specific tools.
[0104] Compared to the shortcomings of existing technologies, research on hybridoma cell construction and monoclonal antibody preparation technologies has not been carried out. There are no hybridoma cell lines that stably secrete specific antibodies, and there is no complete set of standardized immunization-fusion-subcloning-purification processes. It relies solely on commercially available general reagents and cannot independently and stably prepare high-purity specific antibodies on a large scale, which limits the development of kits and targeted drugs. This patent innovatively and non-obviously integrates standardized animal immunization protocols, electrofusion cell screening processes, multi-round monoclonal subclonal line determination procedures, hybridoma cell patent preservation, and Protein G affinity antibody purification processes into a single system, establishing a stable, mass-producible cell resource and antibody preparation system. Hybridoma cell resources that can be stably passaged and stably secrete antibodies have been constructed and disclosed: two hybridoma cell lines, 4G7G5 (CCTCC NO:C202683) and 7G7F9 (CCTCC NO:C202684), have been deposited in the China Type Culture Collection and the preservation center has completed the survival verification. They can be stably preserved for a long time and can be revived and passaged indefinitely, which solves the shortcoming of existing technologies that lack independent and specific cell lines. Establish a complete set of standardized, mass-producible antibody preparation processes (M1-M4 four-stage complete process): The M1 phase standardized Balb / c mouse immunization protocol, with fixed antigen dosage, immunization cycle, and ELISA titer determination criteria, consistently obtained mice with high immune titers; The M2 stage standardized electrofusion and HAT screening system fixes cell ratios and culture conditions to obtain positive fusion cells in batches. In the M3 phase, multiple rounds of limiting dilution subcloning were performed until the cell supernatant was 100% positive, ensuring the purity of the monoclonal cells. The standardized procedure of serum-free suspension expression + Protein G affinity chromatography purification in the M4 stage can stably obtain 1.9 mg (4G7G5) and 2.0 mg (7G7F9) of high-purity antibody in a single purification. Achieve independent and controllable large-scale production: Without the need to purchase commercially available universal antibodies, high-purity anti-PKCδ monoclonal antibodies can be continuously produced in batches based on preserved cell lines and standardized processes, supporting the industrialization research and development of diagnostic kits and targeted drugs; Antibody purity standardization verification: SDS-PAGE electrophoresis (Figure 1) confirmed that the purified antibody had clear 55KD heavy chain and 25KD light chain bands, with a purity ≥90%. A unified purity quality control standard was established, as there is no corresponding standardized purification process and quality control method in the existing technology.
[0105] Compared to the shortcomings of existing technologies, the lack of SPR surface plasmon resonance detection technology completely lacks quantitative data on antigen-antibody binding kinetics. It also lacks core affinity parameters such as Ka binding rate constant, Kd dissociation rate constant, and KD dissociation constant, making it impossible to standardize the evaluation of the binding activity and stability of target molecules and making it difficult to complete the quality control optimization of targeted reagents. This patent innovatively and non-obviously applies the Biacore 8K SPR detection platform, the CM5 chip amino-coupling standardized process, and the 1:1 Langmuir kinetic fitting model to the quantitative characterization of affinity for human PKCδ-monoclonal antibodies, establishing a complete standardized affinity evaluation system and filling a gap in existing technologies. Establish a complete SPR quantitative detection experimental system: clarify the standardized operating procedures for the instrument, chip, buffer, solvent calibration, and regeneration conditions (Figures 2 and 3 are schematic diagrams of the SPR principle). Existing technologies do not cover this type of quantitative characterization method at all. Precise quantification of the core kinetic parameters of the two antibody groups and natural human PKCδ: 4G7G5: KD=2.26×10⁻ 9 M (high affinity), Ka=1.50×10 5 1 / Ms, Kd=3.39×10⁻ 4 1 / s; 7G7F9: KD=8.57×10⁻ 9 M, Ka = 8.10 × 10 4 1 / Ms, Kd=6.94×10⁻ 4 1 / s; The smaller the KD value, the stronger the affinity between the antibody and the target protein. This set of quantitative data can objectively distinguish the performance of different targeting antibodies. Real-time visualization of molecular interaction curves: SPR response sensor maps of antibodies at gradient concentrations of 0.3125~10nM are collected (Figures 4 and 5), which intuitively show the entire process of binding and dissociation, enabling standardized quality control and iterative optimization of the performance of targeted molecules; A reusable affinity evaluation standard is established: subsequent novel PKCδ targeting reagents can all adopt the SPR experimental procedure of this patent, and use the Ka / Kd / KD parameters to complete performance benchmarking, which solves the defect of existing technologies that can only qualitatively evaluate the binding ability of targeting molecules but cannot quantitatively evaluate them.
[0106] Compared to existing technologies, which are limited to laboratory mechanism verification and lack standards for antibody purity and potency quality control, product parameters such as buffer formulations suitable for long-term storage and fixed concentrations / volumes, as well as mass production biological reagent solutions, these technologies only verify the value of a single target and cannot simultaneously meet the industrialization needs of multiple scenarios, including basic scientific research, clinical in vitro diagnostics, and in vivo disease intervention. This patent innovatively and non-obviously integrates unified antibody quality control indicators, standardized long-acting preservation buffer formulations, multi-scenario product application solutions, complete components of diagnostic reagent kits, and AD treatment drug application pathways to build a complete industrialization transformation system, thus opening up the industrialization link from laboratory targets to end products: Establish unified quality control standards for industrialization (fully covering three core indicators: purity, potency, and affinity): Purity control: SDS-PAGE electrophoresis determines purity ≥90%; Potency quality control: Indirect ELISA standard procedure, human PKCδ potency threshold ≥1093.5K; Affinity quality control: SPR determination KD≤10⁻ 8 M serves as the criterion for determining a qualified targeted reagent; Existing technologies lack any quality control thresholds suitable for large-scale production. We present a standardized antibody buffer system that can be mass-produced and stored stably for a long time: a uniform formula of PBS pH 7.4 + 1% sucrose + 0.05‰ preservative, a fixed product aliquot concentration (4G7G5: 0.95mg / mL; 7G7F9: 1.00mg / mL), a uniform aliquot volume of 2.0mL, and is compatible with long-term low-temperature storage of reagent kits and injectable formulations, thus solving the shortcomings of laboratory reagents that lack standardized storage solutions and cannot be mass-produced and aliquoted. Expanding multi-dimensional industrial application scenarios and breaking through the limitations of single basic research: Scenario 1 (Clinical In Vitro Diagnostics): Using 4G7G5 / 7G7F9 monoclonal antibodies to prepare an AD cerebrospinal fluid PKCδ detection kit to achieve quantitative detection of early AD biomarkers and make up for the lack of self-developed diagnostic reagents in existing technologies; Scenario 2 (In vivo disease intervention drugs): Specific monoclonal antibodies target and bind to PKCδ microglia in the brain, inhibiting the NF-κB inflammatory pathway, and are used to prepare drugs for the treatment of Alzheimer's disease and neuroinflammatory-related diseases, replacing the severely off-target effects of rodellrin; Scenario 3 (Basic Research Tools): Purified highly specific antibodies can be used for immunofluorescence, Western blotting, and qPCR protein quantification, replacing commercial broad-spectrum reagents; A complete industrialization transformation platform: It includes a full set of supporting biological materials such as publicly available hybridoma cell preservation resources, recombinant expression vectors, and engineered host cells (mammals / yeast / E. coli), forming a complete productization chain from cell lines to antibody raw materials to diagnostic kits to targeted drugs, solving the core shortcoming of existing technologies that only complete target mechanism verification but lack any industrialization solutions.
[0107] The existing technology has only completed the scientific value verification of the PKCδ target, but it is completely blank in the four key industrialization links: specific target molecules, mass production cell process, quantitative characterization of affinity, and industrialization quality control system. This invention provides a novel, complete, and feasible technical solution to address four major shortcomings: obtaining stable targeted antibody raw materials through patented preservation of hybridoma cells; achieving mass production through standardized immunopurification processes; establishing objective evaluation standards for targeted molecules using the SPR quantitative system; and realizing the transformation of diagnostic and therapeutic products through supporting quality control / preservation formulas and multi-scenario application solutions. All technical means are mutually supportive and logically consistent, fully adhering to the basic physicochemical laws of molecular immunology, biophysical SPR optical detection, and protein biochemical purification. The solution cannot be easily derived from existing technologies, demonstrating outstanding inventiveness and non-obviousness.
[0108] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the claims.
Claims
1. Monoclonal antibody 7G7F9 against human protein kinase CPKC, wherein, The monoclonal antibody comprises a heavy chain variable region sequence and a light chain variable region sequence, characterized in that: The amino acid sequence of the heavy chain variable region is qvqleqsggdlvkpggslklscaasgftfsnyamswirltpekklewvatistassytyysdsvkgrftisrdnvkntlylqmsslrsedtaiyycarqgttvvdfdywgqgttltvss; The amino acid sequence of the light chain variable region is divltqspsslsaslgdrvtiscrasqdisnylnwyqqkadgtvklliyyisrlhsgvpsrfsgsgsgtdfsltitnleqediatyfcqqgnslpwtfgggtklelk.
2. The monoclonal antibody 7G7F9 against human protein kinase CPKC as described in claim 1, characterized in that, The dissociation constant (KD) between the monoclonal antibody and the PKC protein is 8.57 × 10⁻ 9 M, the binding rate constant (Ka) is 8.10 × 10⁻⁶. 4 1 / Ms, the dissociation rate constant (Kd) is 6.94 × 10⁻ 4 1 / s; the purity of the monoclonal antibody was ≥90% as determined by SDS-PAGE electrophoresis; the titer of the monoclonal antibody against human PKC / PKCδ protein was ≥1093.5K as determined by indirect ELISA; the monoclonal antibody was preserved in a buffer solution containing PBS pH7.4 + 1% sucrose + 0.05‰ preservative, with a concentration of 1.00 mg / mL and a volume of 2.0 mL.
3. A nucleic acid molecule encoding the heavy chain variable region and / or light chain variable region of the monoclonal antibody 7G7F9 of claim 1, characterized in that: The nucleic acid sequence of the heavy chain variable region is caggtccagctggagcagtctggggagacttagtgaagcctggagggtccctgaaactctcctgtgcagcctctggattcactttcagtaactatgccatgtcttggattcgcctgactccggagaagaagctggagtgggtcgcaaccattagtactgctagtagttacac ctactattcagacagtgtgaaggggcgattcaccatctccagagacaatgtcaagaacaccctgtacctacaaatgagcagtctgaggtctgaggacacggccatatattactgtgcaagacaggggactacggtagtggactttgactactggggccaaggcaccactctcacagtctcctca; The nucleic acid sequence of the light chain variable region is gacattgtgctcacccagtctccatcatccctgtctgcctctctggggagacagtcaccatcagttgcagggcaagtcaggacattagcaattatttaaactggtatcagcagaaagcagatggaactgttaaactcctgatctactacatatc aagattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagatttttctctcaccattaccaacttggaacaagaagatattgccacttacttttgccaacagggtaattcgcttccgtggacgttcggtggaggcaccaagctagaactcaaa.
4. A recombinant expression vector, characterized in that: The carrier contains the nucleic acid molecule as described in claim 2.
5. A recombinant host cell, characterized in that: The host cell expresses the monoclonal antibody 7G7F9 as described in claim 1, and the host cell is selected from mammalian cells, yeast cells or Escherichia coli cells.
6. A hybridoma cell line, characterized in that: The hybridoma cell line can secrete the monoclonal antibody 7G7F9 as described in claim 1. The hybridoma cell line was deposited at the China Committee for Type Culture Collection (CCTCC) on June 11, 2026, with accession number CCTCC NO:C202684.
7. The use of the monoclonal antibody 7G7F9 of claim 1, the nucleic acid molecule of the heavy chain variable region and / or light chain variable region of the monoclonal antibody 7G7F9 of claim 3, the recombinant expression vector of claim 4, the recombinant host cell of claim 5, and the hybridoma cell line of claim 6 in the preparation of diagnostic reagents or diagnostic kits for detecting human PKC protein.
8. The use of the monoclonal antibody 7G7F9 of claim 1, the nucleic acid molecule of the heavy chain variable region and / or light chain variable region of the monoclonal antibody 7G7F9 of claim 3, the recombinant expression vector of claim 4, the recombinant host cell of claim 5, and the hybridoma cell line of claim 6 in the preparation of a medicament for the treatment of Alzheimer's disease (AD) or neuroinflammatory-related diseases.
9. A diagnostic reagent kit, characterized in that: The diagnostic kit contains the monoclonal antibody 7G7F9 as described in claim 1.
10. A method for preparing a monoclonal antibody 7G7F9 against human protein kinase CPKC, characterized in that, It includes the following steps: Phase 1 (M1): Animal immunization and antiserum titer assessment: Antiserum is prepared from animals immunized with antigens, the antiserum titer is assessed, and a GO / NO-GO decision is made; Phase Two (M2) Cell Fusion Screening Phase: Cell fusion to obtain antigen-specific fusion cell lines; Phase 3 (M3): Cell subcloning and line determination: Cell subcloning obtains single-clone cell lines specific to the antigen; Phase 4 (M4): Antibody expression and purification phase: Antibody purification yields more than 1 mg of specific antibody.
